Literature DB >> 22395995

Outcome of patients with ductal carcinoma in situ and sentinel node biopsy.

T J Meretoja1, P S Heikkilä, K Salmenkivi, M H K Leidenius.   

Abstract

BACKGROUND: In sentinel node biopsy (SNB), tumor-positive findings, mainly micrometastases and isolated tumor cells (ITC) have been found in up to 8%-16% of patients with pure ductal carcinoma in situ (DCIS) or microinvasive DCIS (DCISM). The prognostic significance of such findings is largely unknown. The aim of this study is to examine the outcome of DCIS and DCISM patients with SNB.
METHODS: A total of 280 breast cancer patients with pure or microinvasive DCIS underwent SNB between April 2001 and December 2010 at the Breast Surgery Unit of Helsinki University Central Hospital. Patient, tumor, SNB procedure, and follow-up data were gathered. The median follow-up was 50 months (range 7-123 months).
RESULTS: Altogether, 21 patients had tumor-positive sentinel node findings. Of these, 14 were in pure DCIS patients (1 macrometastasis, 1 micrometastasis, 12 ITC) and 7 in DCISM patients (1 macrometastasis, 2 micrometastases, 4 ITC). Also, 16 patients, 10 with pure DCIS and 6 with DCISM, underwent completion axillary lymph node dissection (ALND). Only 1 of them, a patient with DCISM, had additional tumor positive finding in the ALND. During a median follow-up of 50 months (range 7-123 months) there were 5 local recurrences. One patient with pure DCIS and tumor-negative SNB developed overt axillary metastases and later also distant metastases.
CONCLUSIONS: DCIS and DCISM patients do have tumor positive findings, but a majority of these are ITC or micrometastases. In light of this study, these findings do not affect the outcome of DCIS or DCISM patients.

Entities:  

Mesh:

Year:  2012        PMID: 22395995     DOI: 10.1245/s10434-012-2287-5

Source DB:  PubMed          Journal:  Ann Surg Oncol        ISSN: 1068-9265            Impact factor:   5.344


  7 in total

1.  Is Sentinel Lymph Node Biopsy Indicated at Completion Mastectomy for Ductal Carcinoma In Situ?

Authors:  Melissa Pilewskie; Maria Karsten; Julia Radosa; Anne Eaton; Tari A King
Journal:  Ann Surg Oncol       Date:  2016-03-09       Impact factor: 5.344

2.  The Role of Sentinel Lymph Node Biopsy and Factors Associated with Invasion in Extensive DCIS of the Breast Treated by Mastectomy: The Cinnamome Prospective Multicenter Study.

Authors:  Christine Tunon-de-Lara; Marie Pierre Chauvet; Marie Christine Baranzelli; Marc Baron; Jean Piquenot; Guillaume Le-Bouédec; Fréderique Penault-Llorca; Jean-Rémi Garbay; Jérôme Blanchot; Joëlle Mollard; Véronique Maisongrosse; Simone Mathoulin-Pélissier; Gaëtan MacGrogan
Journal:  Ann Surg Oncol       Date:  2015-03-17       Impact factor: 5.344

Review 3.  Current approach and future perspective for ductal carcinoma in situ of the breast.

Authors:  Chizuko Kanbayashi; Hiroji Iwata
Journal:  Jpn J Clin Oncol       Date:  2017-08-01       Impact factor: 3.019

4.  Risk factors for lymph node metastasis and the impact of adjuvant chemotherapy on ductal carcinoma in situ with microinvasion: a population-based study.

Authors:  Cong Chen; Shumin Huang; Aihua Huang; Yunlu Jia; Ji Wang; Zeqin Zhang; Misha Mao; Linbo Wang; Jichun Zhou
Journal:  Onco Targets Ther       Date:  2018-12-13       Impact factor: 4.147

5.  Preoperative Delays in the Treatment of DCIS and the Associated Incidence of Invasive Breast Cancer.

Authors:  William H Ward; Lyudmila DeMora; Elizabeth Handorf; Elin R Sigurdson; Eric A Ross; John M Daly; Allison A Aggon; Richard J Bleicher
Journal:  Ann Surg Oncol       Date:  2019-09-27       Impact factor: 5.344

6.  Patterns of treatment and outcome of ductal carcinoma in situ in the Netherlands.

Authors:  Jacky D Luiten; Ernest J T Luiten; Maurice J C van der Sangen; Willem Vreuls; Lucien E M Duijm; Vivianne C G Tjan-Heijnen; Adri C Voogd
Journal:  Breast Cancer Res Treat       Date:  2021-01-01       Impact factor: 4.872

7.  Sentinel node mapping for breast cancer: current situation.

Authors:  Sergi Vidal-Sicart; Renato Valdés Olmos
Journal:  J Oncol       Date:  2012-08-15       Impact factor: 4.375

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.